Pharmaceutical equipment spending reached USD 27.10 billion in 2026 and is forecast to USD 33.79 billion by 2031 at a 4.51% CAGR, with aseptic fill-finish systems capturing 29.55% revenue share and North America holding 42.52% of global spend [S1].
Biologics now account for 85% of pipeline manufacturing runs, pushing installed global bioreactor volume from 6.7 million L toward 8.9 million L by 2028, and CDMOs are projected to command 38% of bioreactor capacity by 2028 versus 28% in 2024 [S1].
Market Size and 2026 Baseline Across the Main Trackers
Forecast vendors disagree on absolute size because they slice the value chain differently, but the directional reading is consistent: the equipment base expanded in 2026 and the incremental opportunity is concentrated in biologics-ready capacity. [S4]
Mordor Intelligence values the pharmaceutical equipment market at USD 25.93 billion in 2025, USD 27.10 billion in 2026, and USD 33.79 billion by 2031, a 4.51% CAGR [S1]. Market Research Future (MRFR) reads the broader equipment and adjacent instrumentation stack at USD 53.26 billion in 2025 rising to USD 68.25 billion by 2035 at 2.51% CAGR [S2]. Technavio sizes the 2025 to 2030 incremental opportunity at USD 5.88 billion at 6.1% CAGR, with North America contributing 38.3% of the growth [S3].
Future Market Insights isolates the continuous-manufacturing equipment subset at USD 1.6 billion in 2026, growing at 9.6% CAGR to USD 4.08 billion by 2036, a faster rate than the broader mix because flow skids replace batch assets one line at a time [S4]. Research and Markets reads the manufacturing equipment tier at USD 20.7 billion in 2025, reaching USD 37.42 billion by 2034 at 6.8% CAGR [S5]. Fortune Business Insights projects USD 25.14 billion in 2026 climbing to USD 46.21 billion by 2034 at 7.9% CAGR [S6]. Market Growth Reports lands the highest, with global pharmaceutical manufacturing and processing equipment at USD 68.50 billion in 2026 [S7].
For procurement teams the practical takeaway is that the lower-bound trackers (Mordor, Research and Markets) reflect the equipment-only line items that show up on a capital PO, while the upper-bound trackers (MRFR, Market Growth Reports) bundle laboratory, quality-control, and adjacent instrumentation into a wider envelope [S1][S2][S7].
Equipment Type Mix: Aseptic Fill-Finish Leads, Continuous Manufacturing Fastest
Aseptic fill-finish systems led the 2025 equipment mix with 29.55% revenue share, while quality-control and inspection instruments are advancing at 4.85% CAGR through 2031, the fastest non-continuous slice [S1].
The European Medicines Agency's Annex 1 revision obliges isolators or restricted-access barrier systems (RABS) across roughly 1,200 European fill-finish suites, a multiyear retrofit backlog that anchors near-term aseptic demand regardless of biologics growth [S1]. Within fill-finish, viral-vector lines are the binding constraint, with 18 to 24 month equipment lead times that directly gate gene-therapy launches [S1].
Drug substance production accounted for 36.53% of 2025 equipment spend, but quality-control and release testing is the fastest-growing manufacturing stage at 5.75% CAGR through 2031 as PAT and rapid microbiology tools replace offline sampling [S1]. On the product side, solid dosage equipment was valued at USD 9.96 billion in 2024, anchored by high-shear mixers, fluid bed granulation, roller compaction, and micronization for bioavailability [S3].
Continuous manufacturing equipment is the structurally fastest-growing slice: 9.6% CAGR from 2026 to 2036, with dryers at 35.0% of the device-type segment and medicines at 71.2% of the application segment [S4]. India leads country-level growth at 12.0% CAGR, with Germany at 11.0%, and Gericke and Readco Kurimoto cited as established suppliers scaling production capacity to match [S4].
End-User and Regional Split: Big Pharma Spend, CDMO Acceleration, APAC Catch-Up
Big Pharma held 42.15% of 2025 equipment spend, but CDMOs and CMOs are growing faster at 5.82% CAGR through 2031 as outsourcing consolidates purchasing power [S1].
The CDMO share of global bioreactor capacity is projected to rise from 28% in 2024 to 38% by 2028, a 10-point swing that pulls investment toward flexible, modular, single-use skids rather than fixed stainless-steel plants [S1]. That pivot is what allows validation timelines to compress from roughly 18 months on traditional stainless installations to under 6 months on single-use assemblies, a figure that materially changes capex IRR for greenfield biologics lines [S1].
Regionally, North America captured 42.52% of 2025 spend per Mordor, and Technavio attributes 38.3% of 2025 to 2030 growth to the same region [S1][S3]. Asia-Pacific is the fastest-growing region at 5.12% CAGR through 2031 per Mordor, consistent with the continuous-manufacturing reading where India alone runs at 12.0% CAGR [S1][S4]. FDA advanced-manufacturing fast-tracking is shortening commercial approval by 6 to 9 months for facilities that deploy continuous or single-use platforms, which tilts the regional capex race further toward U.S. early adopters and Indian capacity expansions [S1].
Technology Drivers and Vendor Map
Single-use assemblies, continuous flow, and Pharma 4.0 retrofits are the three technology vectors doing the most to reshape vendor market share in 2026, with regulatory pressure as the forcing function behind all three [S1][S3].
Mordor's driver-impact decomposition attributes +1.2% CAGR to rising biologics volumes, +0.9% to single-use adoption, +0.7% to GMP-driven upgrades, +0.8% to contract manufacturing expansion, +0.5% to continuous manufacturing, and +0.4% to Pharma 4.0 predictive-maintenance retrofits, with the United States and Germany leading the latter [S1]. Vendor concentration in the broader tracker is high: Thermo Fisher Scientific, Abbott Laboratories, Becton Dickinson, Siemens Healthineers, GE Healthcare, Roche Diagnostics, Agilent, PerkinElmer, and Eppendorf are the named majors [S2]. Within continuous manufacturing specifically, Gericke and Readco Kurimoto are positioned as established multi-market suppliers with the production scale to capture the India and Germany waves [S4].
For spec-writing engineers the shortlist to evaluate on 2026 RFQs is: single-use bioreactor and mixing assemblies (driven by CDMO biologics), isolator and RABS retrofit packages (driven by Annex 1), continuous-flow skids with integrated PAT (driven by the 9.6% CAGR subset), and predictive-maintenance instrumentation layers that slot into existing lighting equipment and electric lamps and cleanroom utility headers without revalidation [S1][S3][S4].
Selection Criteria, Constraints, and Failure Modes
Specifying 2026 pharmaceutical equipment comes down to four binding constraints: Annex 1 containment, biologics-ready single-use flow, validation cycle time, and supply-chain redundancy for long-lead items like bioreactors and isolators. [S1]
The most common spec failure is sizing a fill-finish line for traditional small-molecule throughput and then bolting on viral-vector capacity two years later, by which point isolator lead times have stretched past 18 months [S1]. A second failure mode is choosing a single-use platform without auditing extractables and leachables data against the specific biologic; the validation savings evaporate if the cell-culture performance drifts between batches.
On the procurement side, the equipment-only lower-bound estimates (USD 25.93 to 27.10 billion in 2025 to 2026) are the right benchmarks for capex planning, while the upper-bound figures (USD 51.96 to 68.50 billion) overstate capital spend because they bundle laboratory, diagnostics, and adjacent instrumentation that typically runs through opex rather than capex [S1][S2][S7]. Engineers specifying process skids should anchor on the slice definitions, not the headline totals.
For plants that run continuous flow skids, a practical 2026 constraint is the limited second-source base for integrated dryer-granulator-reactor assemblies, which makes Gericke- and Readco Kurimoto-class suppliers single-thread on critical lines [S4]. For plants retrofitting Annex 1, the binding constraint is not the isolator itself but the surrounding construction machinery and equipment envelope: room pressurization, airlocks, and VHP decontamination cycles, which must be revalidated together.
Competitive Landscape Reading: Where the Specs Actually Land
The 2026 competitive landscape is best read as three overlapping races, with the same vendors appearing across all three. [S5]
Race one is aseptic fill-finish share, where Annex 1 retrofit backlog favors incumbents with installed European service networks and FDA-accepted isolator documentation [S1]. Race two is continuous-flow skids, where the 9.6% CAGR through 2036 favors process-equipment specialists with PAT and digital-twin integration rather than generalist packaging vendors [S3][S4]. Race three is Pharma 4.0 instrumentation, where the industrial automation software layer is increasingly bundled with equipment warranties, pulling MES, SCADA, and predictive-maintenance decisions upstream of the equipment PO.
For CDMO buyers, the practical 2026 decision is whether to standardize on a single-vendor single-use platform (lower integration risk, higher single-thread exposure) or on a multi-vendor open-architecture approach (higher validation cost, better supply resilience). The market data tilts the answer toward open architecture as bioreactor capacity share migrates from Big Pharma's 42.15% to a more distributed CDMO base growing at 5.82% CAGR [S1].
Trackable signals for the next 12 months: Annex 1 retrofit award announcements from European fill-finish operators, FDA advanced-manufacturing designations for continuous-flow lines, and 2027 capex guidance from the named majors on biologics and CDMO capacity additions [S1][S3][S4]. The 2026 to 2030 incremental opportunity of USD 5.88 billion per Technavio is the cleanest single number to size near-term RFQ pipelines against [S3].
Component reference pages worth checking: ndt equipment.